Erica Elchin - Aziyo Biologics VP Operations

AZYODelisted Stock  USD 2.44  0.00  0.00%   

Insider

Erica Elchin is VP Operations of Aziyo Biologics
Phone240 247 1170
Webhttps://www.aziyo.com

Aziyo Biologics Management Efficiency

The company has return on total asset (ROA) of (0.2875) % which means that it has lost $0.2875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7514) %, meaning that it created substantial loss on money invested by shareholders. Aziyo Biologics' management efficiency ratios could be used to measure how well Aziyo Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
Aziyo Biologics currently holds 34.89 M in liabilities with Debt to Equity (D/E) ratio of 3.5, implying the company greatly relies on financing operations through barrowing. Aziyo Biologics has a current ratio of 0.98, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Aziyo Biologics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Kerr HolbrookAvanos Medical
57
Nikolai KabelevSTRATA Skin Sciences
48
Anthony SemedoArtivion
69
Joshua WellsArtivion
N/A
Charles IIIAnika Therapeutics
N/A
Patrick MercerIRIDEX
52
Jean HollowayArtivion
63
Joel BradusNexalin Technology
N/A
Scott CappsArtivion
53
Mark QuickOrthofix Medical
N/A
Rajbir DenhoyEstablishment Labs Holdings
53
Brad NagelElectromed
N/A
Marilyn ElsonNexalin Technology
71
Andrew GreenArtivion
52
Moji JamesAvanos Medical
N/A
Keith SimeoneSTRATA Skin Sciences
N/A
Thomas AckermanArtivion
66
Paul BadawiSight Sciences
49
Matthew GetzArtivion
55
David ColleranAnika Therapeutics
52
Bart BracyAnika Therapeutics
N/A
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic devicecardiovascular, orthopedicspinal repair, and soft tissue reconstruction markets. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland. Aziyo Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 162 people. Aziyo Biologics (AZYO) is traded on NASDAQ Exchange in USA and employs 151 people.

Management Performance

Aziyo Biologics Leadership Team

Elected by the shareholders, the Aziyo Biologics' board of directors comprises two types of representatives: Aziyo Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aziyo. The board's role is to monitor Aziyo Biologics' management team and ensure that shareholders' interests are well served. Aziyo Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aziyo Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Erica Elchin, VP Operations
Matthew Ferguson, Chief Officer
Randal Mills, Pres CoFounder
MS MBA, Ex Chairman
Michelle Williams, Chief Officer
Jeffry Hamet, Treasurer Fin
Sonali Fonseca, Head Buses
Courtney Guyer, VP Marketing
Thomas Englese, Chief Officer

Aziyo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aziyo Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Aziyo Biologics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aziyo Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aziyo Biologics will appreciate offsetting losses from the drop in the long position's value.

Moving against Aziyo Stock

  0.69EC Ecopetrol SA ADRPairCorr
  0.61BA Boeing Fiscal Year End 29th of January 2025 PairCorr
  0.57SHG Shinhan FinancialPairCorr
  0.5MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.39WF Woori Financial GroupPairCorr
The ability to find closely correlated positions to Aziyo Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aziyo Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aziyo Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aziyo Biologics to buy it.
The correlation of Aziyo Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aziyo Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aziyo Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aziyo Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in Aziyo Stock

If you are still planning to invest in Aziyo Biologics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aziyo Biologics' history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules